id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-3650-0007,FDA,FDA-2017-E-3650,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-08-05T04:00:00Z,2019,8,2019-08-05T04:00:00Z,,2019-08-05T13:12:36Z,,0,0,0900006483df1feb
FDA-2017-E-3650-0006,FDA,FDA-2017-E-3650,"Determination of Regulatory Review Period for Purposes of Patent
Extension; OCALIVA",Notice,Determinations,2018-12-04T05:00:00Z,2018,12,2018-12-04T05:00:00Z,2019-02-05T04:59:59Z,2018-12-04T14:17:27Z,2018-26288,0,0,0900006483939066
FDA-2017-E-3650-0005,FDA,FDA-2017-E-3650,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-11-20T05:00:00Z,2018,11,2018-11-20T05:00:00Z,,2018-11-20T13:23:38Z,,0,0,09000064838eb878
FDA-2017-E-3650-0004,FDA,FDA-2017-E-3650,Letter from  the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T15:48:19Z,,0,0,090000648378c30d
FDA-2017-E-3650-0003,FDA,FDA-2017-E-3650,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-09-21T04:00:00Z,2017,9,2017-09-21T04:00:00Z,,2017-09-21T14:08:54Z,,0,0,0900006482b69a8a
FDA-2017-E-3650-0002,FDA,FDA-2017-E-3650,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2017-06-09T04:00:00Z,2017,6,2017-06-09T04:00:00Z,,2017-06-09T18:48:16Z,,0,0,09000064826b9551
FDA-2017-E-3650-0001,FDA,FDA-2017-E-3650,Patent Extension Application from Cooley LLP (on behalf of Intercept Pharmaceuticals Inc),Other,Application,2017-06-09T04:00:00Z,2017,6,2017-06-09T04:00:00Z,,2017-06-09T18:37:54Z,,0,0,09000064826b8f14